The road to embryologically based dose-response models

Environmental Health Perspectives

Volumn 104, Issue SUPPL. 1, 1996, Pages 107-121

  Kavlock, Robert J ^a   Setzer, R Woodrow ^a  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

BBDR; Benchmark dose; Biologically based dose response models; Developmental toxicity; Homeobox; Limb development; Mathematical models; Pattern formation; RfD; Risk assessment; Skeletal development; Teratogencity

Indexed keywords

ENVIRONMENTAL CHEMICAL;

BIRTH DEFECT; BONE DEVELOPMENT; DOSE RESPONSE; EMBRYOLOGY; HOMEOBOX; LIMB DEVELOPMENT; LOW BIRTH WEIGHT; MATHEMATICAL MODEL; METHODOLOGY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SPONTANEOUS ABORTION; TERATOGENICITY;

EID: 0029882011     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.96104s1107     Document Type: Review

References (88)

1. U.S. Environmental Protection Agency. Guideline for developmental toxicity risk assessment. Federal Register 56:63798-63826 (1991).
2. National Research Council. Risk Assessment in the Federal Government: Managing the Process. Washington:National Academy Press, 1983.
3. Barnes D, Dourson ML. Reference dose (RfD): description and use in health risk assessment. Regul Toxicol Pharmacol 8:471-486 (1988).
4. Moore JA, Daston GP, Faustman E, Golub MS, Hart WL, Hughes C, Kimmel CA , Lamb JC IV, Schwetz BA, Scialli AR. An evaluative process for assessing human reproductive and developmental toxicity of agents. Reprod Toxicol 9:61-95 (1995).
5. Clark RL, Robertson RT, Peter CP, Bland JA, Nolan TE, Oppenheimer L, Bokelman DL. Association between adverse maternal and embryo-fetal effects in norfloxacin-treated and food-deprived rabbits. Fundam Appl Toxicol 7:272-286 (1986).
6. Clark RL, Robertson RT, Minsker DH, Cohen S, Tocco J, Allen HL, Jones ML, Bokelman DL. Diflunisal-induced maternal anemia as a cause of teratogenicity in animals. Teratology 30:319-332 (1984).
7. Moore JA, IEHR Expert Scientific Committee. An assessment of lithium using the IEHR evaluative process for assessing the human developmental and reproductive toxicity of agents. Reprod Toxicol 9:175-210 (1995).
8. Gaylor D. Incidence of developmental effects at the no observed adverse effect level (NOAEL). Regul Toxicol Pharmacol 15:151-160 (1992).
9. Leisenring W, Ryan L. Statistical properties of the NOAEL. Regul Toxicol Pharmacol 15:161-171 (1992).
10. Crump K. A new method for determining allowable daily intakes. Fundam Appl Toxicol 4:854-871 (1984).
11. Barnes DR, Daston GP, Evans JS, Jarabek AM, Kavlock RJ, Kimmmel CA, Park C, Spitzer H. Benchmark dose workshop: criteria for use of a benchmark dose to estimate a reference dose. Regul Toxicol Pharmacol 21:296-306 (1995).
12. Faustman EM, Allen BC, Kavlock RJ, Kimmel CA. Dose-response assessment for developmental toxicity. I. Characterization of database and determination of the no observed adverse effect levels. Fundam Appl Toxicol 23:478-486 (1994).
13. Allen BC, Kavlock RJ, Kimmel CA, Faustman EM. Dose-response assessment for developmental toxicity. II. Comparison of generic benchmark dose estimates with no observed adverse effect levels. Fundam Appl Toxicol 23:487-495 (1994).
14. Allen B, Kavlock RJ, Kimmel CA, Faustman EM. Dose-response assessment for developmental toxicity. III. Statistical models. Fundam Appl Toxicol 23:496-509 (1994).
15. Kavlock RJ, Allen BC, Faustman EM, Kimmel CA. Dose-response assessment for developmental toxicity. IV. Benchmark doses for fetal weight changes. Fundam Appl Toxicol 26:211-222 (1995).
16. Catalano PJ, Scharfstein DO, Ryan LM, Kimmel CA, Kimmel GL. Statistical model for fetal death, fetal weight, and malformation in developmental toxicity studies. Teratology 47:281-290 (1993).
17. Zhu Y, Krewski D, Ross WH. Dose-response models for correlated multinomial data from developmental toxicity studies. Appl Stat 43:583-598 (1994).
18. Krewski D, Zhu Y. Applications of multinomial dose-response models in developmental toxicity risk assessment. Risk Anal 14:595-609 (1994).
19. Shuey DL, Lau C, Logsdon TR, Zucker RM, Elstein KH, Narotsky MG, Setzer RW, Kavlock RJ, Rogers JM. Biologically based dose-response models for developmental toxicology: biochemical and cellular sequelae of 5-fluorouracil exposure in the developing rat. Toxicol Appl Pharmacol 126:129-144 (1994).
20. Kavlock RJ, Schmid J, Setzer RW. A simulation study of the influence of study design on the estimation of benchmark doses for developmental toxicity. Risk Anal (in press).
21. Tukey J, Ciminera J, Heyse B. Testing the statistical certainty of a response to increasing dose of a drug. Biometrics 41:295-301 (1985).
22. Conolly RB, Andersen ME. Biologically based pharmacodynamic models. Annu Rev Pharmacol Toxicol 31:503-523 (1991).
23. Frederick C. Limiting the uncertainty in risk assessment by development of physiologically based pharmacokinetic models. Toxicology 68:159-175 (1993).
24. Gaylor D, Razzaghi M. Process of building biologically based dose-response models for developmental defects. Teratology 46:573-581 (1992).
25. Leisenring WM, Leroux BG, Moolgavkar SH, Faustman EM. Evaluation of cellular kinetics in biologically based dose-response models for developmental toxicity. Teratology 47: 426 (1993).
26. Setzer RW. Development of biologically based dose-response models: modeling the effects of 5-FU on cell cycle kinetics. Teratology 47:435-436 (1993).
27. Setzer RW. Development of biologically based dose response models: using a mechanistic model to generate experimentally testable hypotheses about mechanisms of developmental toxicity of 5-FU. Teratology 49:396-397 (1994).
28. Lau C, Copeland MF, Mole L, Setzer RW, Rogers JM, Kavlock RJ. Development of a biologically based dose-response (BBDR) model for the embryotoxicity of 5-fluorouracil (5-FU) in the rat. Teratology 51:188 (1995).
29. Collins JM, Dedrick RL, King FG, Speyer JL, Myers CE. Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes. Clin Pharmacol Ther 28:235-246 (1980).
30. O'Flaherty EJ, Scott W, Schreiner C, Beliles RP. A physiologically based kinetic model of rat and mouse gestation: disposition of a weak acid. Toxicol Appl Pharmacol 112:245-256 (1992).
31. Boike GM, Deppe G, Young JD, Malone JM, Malviya VK, Sokol RJ. Chemotherapy in a pregnant rat model. 2. 5-Fluorouracil: nonlinear kinetics and placental transfer. Gynecol Oncol 34:191-194 (1989).
32. Jackson RC. A kinetic model of regulation of the deoxyribonucleoside triphosphate pool composition. Pharmacol Ther 24:279-301 (1984).
33. Nagarajan M, Johnson LF. Regulation of thymidylate gene expression in mouse fibroblasts synchronized by mitotic selection. Exp Cell Res 181:289-297 (1989).
34. McGinnis W, Garbar RL, Wirz J, Kuroiwa A, Gehring WJ. A homologous protein-coding sequence in Drosophila homeotic genes and its conservation in other metazoans. Cell 37:403-408 (1984).
35. Krumlauf R. Hox genes in vertebrate development. Cell 78:191-201 (1994).
36. Manak JR, Scott MP. A class act: conservatism of home-odomain protein functions. Development 1994 Suppl: 61-71 (1994).
37. Burke AC, Nelson CE, Morgan BA, Tabin C. Hox genes and the evolution of vertebrate axial morphology. Development 121:333-346 (1995).
38. Schneider-Maunoury S, Topilko P, Setianidou T, Levi G, Cohen-Tannoudji M, Pournin S, Babinet C, Charnay P. Disruption of Krox-20 results in alteration of rhombomeres 3 and 5 in the developing hindbrain. Cell 75:1199-1214 (1993).
39. Alkema MJ, van der Lugt NMT, Bobeldijk RC, Berns A, van Lohuizen M. Transformation of axial skeleton due to over-expression of bmi-1 in transgenic mice. Nature 374:724-727 (1995).
40. Dietrich S, Schubert FR, Gruss P. Altered Pax gene expression in murine notochord mutants: the notochord is required to initiate and maintain ventral identity in the somite. Mech Dev 44:189-207 (1993).
41. Lufkin T, Dierich A, LeMeur M, Mark M, Chambon P. Disruption of the Hox-1.6 homeoboz gene results in defects in a region corresponding to its rostral domain of expression. Cell 66:1105-1119 (1991).
42. Gendron-Maguire M, Mallo M, Zhang M, Gridley T. Hoxa-2 mutant mice exhibit homeotic transformation of the skeletal elements derived from the neural crest. Cell 75:1317-1331 (1993).
43. Rijli FM, Mark M, Lakkaraju S, Dierich A, Dolle P, Chambon P. A homeotic transformation is generated in the rostral branchial region of the head by disruption of Hoxa-2, which acts as a selector gene. Cell 75:1333-1349 (1993).
44. Condie BG, Capecchi MR. Mice with targeted disruptions in the paralogous genes hoxa-3 and hoxd-3 reveal synergistic interactions. Nature 370:304-307 (1994)
45. Chiska O, Capecchi MR. Regionally restricted developmental defects resulting from targeted disruption of the mouse homeobox gene hox-1.5. Nature 350:473-476 (1991).
46. Condie BG Capecchi, MR. Mice homozygous for a targeted disruption of Hoxd-3 (Hox-4.1) exhibit anterior transformations of the first and second cervical vertebrae, the atlas and axis. Development 119:579-595 (1993).
47. Horan GSB, Wu K, Wolgemuth DJ, Behringer RR. Homeotic transformation of the cervical vertebrae in Hoxa-4 mutant mice. Proc Nad Acad Sci 91:12644-12648 (1994).
48. Kostic D, Capecchi MR. Targeted disruptions of the murine Hoxa-4 and Hoxa-6 genes result in homeotic transformations of components of the vertebral column. Mech of Dev 46:231-247 (1994).
49. Ramirez-Solis R, Zheng H, Whiting J, Krumlauf R, Bradley A. Hoxb-4 (Hox-2.6) mutant mice show homeotic transformation of a cervical vertebra and defects in closure of the sternal rudiments. Cell 73:279-294 (1993).
50. Horan GSB, Nagy Kovacs E, Behringer RR, Featherstone MS. Mutations in paralogous Hox genes result in overlapping homeotic transformations of the axial skeleton: evidence for unique and redundant function. Dev Biol 169:359-372 (1995).
51. Jeannotte L, Lemieux M, Charron J, Poirier F, Robertson, EF. Specification of axial identity in the mouse: role of the Hoxa-5 (Hox1.3) gene. Genes Dev 7:2085-2096 (1993).
52. Rancourt DE, Tsuzuki T, Capecchi MR. Genetic interaction between hoxb-5 and hoxb-6 is revealed by nonallelic noncomplementation. Genes Dev 9:108-122 (1995).
53. Le Mouellic H, Lallemand Y, Brulet P. Homeosis in the mouse induced by a null mutation in the Hox-3.1 gene. Cell 69:251-264 (1992).
54. Suemori H, Takahashi N, Noguchi S. Hoxc-9 mutant mice show anterior transformation of the vertebrae and malformation of the sternum and ribs. Mech Dev 51:265-273 (1995).
55. Small KM, Potter SS. Homeotic transformations and limb defects in Hoxa-11 mutant mice. Genes Dev 7:2318-2328 (1993).
56. Davis AP, Capecchi MR. Axial homeosis and appendicular skeleton defects in mice with a targeted disruption of hoxd-11. Development 120:2187-2198 (1994).
57. Dolle P, Dierich A, LeMeur M, Schimmang T, Schuhbar B, Chambon P, Duboule D. Disrupcion of the Hoxd-13 gene induces localized heterochrony leading to mice with neotonic limbs. Cell 75:431-441 (1993).
58. Kavlock RJ, Chernoff N, Rogers E. The effect of acute maternal toxicity on fetal development in the mouse. Teratog Carcinog Mutagen 5:3-14 (1985).
59. Chernoff N, Miller DB, Rosen MB, Mattscheck CL. Developmental effects of maternal stress in the CD-1 mouse induced by restraint stress on single days during the period of major organogenesis. Toxicology 51:57-65 (1988).
60. Narotsky MG, Francis EZ, Kavlock RJ. Developmental toxicity and structure activity relationships of aliphatic acids, including dose-response assessment of valproic acid in mice and rats. Fundam Appl Toxicol 22:251-265 (1994).
61. Rogers JM, Francis BM, Barbee BD, Chernoff N. Developmental toxicity of bromoxynil in mice and rats. Fundam Appl Toxicol 17:442-447 (1991).
62. Chernoff N, Rogers JM, Turner CI, Francis BM. Significance of supernumerary ribs in rodent developmental toxicity studies: postnatal persistence in rats and mice. Fundam Appl Toxicol 17:448-453 (1991).
63. Kimmel CA, Wilson JG. Skeletal deviation in rats: malformations or variations? Teratology 8:309-316 (1973).
64. Hartley J, Brown NA. Homeotic transformation in the mouse axial skeleton: a dimethadione-induced model. Teratology 50:28-29A (1994).
65. Kessel M, Gruss P. Homeotic transformations of murine vertebrae and concomitant alteration of Hox codes induced by retinoic acid. Cell 67:89-104 (1991).
66. Heindel JJ, Price CJ, Field EA, Marr MC, Myers CB, Morrissey RE, Schwetz BA. Developmental toxicity of boric acid in mice and rats. Fundam Appl Toxicol 18:266-277 (1992).
67. Narotsky MG, Hamby BT, Kavlock RJ. Effects of boric acid on axial skeletal development in rats. Teratology 51:192 (1995).
68. Cherrington JW, Rosen MB, Branch S, Dauterman WC, Chernoff N. Effects of boric acid administered on single days of gestation in the CD-1 mouse. Teratology 51:181 (1995).
69. Rogers JM, Mole ML, Chernoff N, Barbee BD, Turner CI, Logsdon TR, Kavlock RJ. The developmental toxicity of inhaled methanol in the CD-1 mouse, with quantitative dose-response modeling for estimation of benchmark doses. Teratology 47:175-188 (1993).
70. Connelly LE, Rogers JM. Methanol causes posteriorization of cervical vertebrae in the mouse fetus. Teratology 49: 393 (1994).
71. Bryant SV, Gardiner DM. Retinoic acid, local cell-cell interactions, and pattern formation in vertebrate limbs. Dev Biol 152:1-25 (1992).
72. Tickle C, Eichele G. Vertebrate limb development. Annu Rev Cell Biol 10:121-152 (1994).
73. Morgan BA, Tabin C. Hox genes and growth: early and late roles in limb bud morphogenesis. Development Suppl 181-186 (1994).
74. Doboule D. How to make a limb. Science 226:575-576 (1994).
75. Muneoka K, Anderson R. Vertebrate limb development. In: Drug Toxicity in Embryonic Development (Kavlock RJ, Daston GP, ed). Heidelberg:Springer Verlag, in press.
76. Saunders JW, Gasseling M. Ectodermal-mesenchymal interaction in the origin of limb symmetry. In: Epithelial-Mesenchymal Interaction (Flesichmayer R, Billinghman RE, eds). Baltimore:Williams and Wilkins, 1968;78-97.
77. Riddle RD, Johnson RL, Laufer E, Tabin C. Sonic hedgehog mediates the polarizing activity of the ZPA. Cell 75:1401-1416 (1993).
78. Tabin CJ. Why we have (only) five fingers per hand: Hox genes and the evolution of paired limbs. Development 116:289-296 (1992).
79. Tabin CJ. Retinoids, homeoboxes, and growth factors: toward molecular models for limb development. Cell 66:199-217 (1991).
80. Parr BA, McMahon AP. Dorsalizing signal Wnt-7a required for normal polarity of D-V and A-P axes of mouse limb. Nature 374:350-353 (1995).
81. Turing A. The chemical basis of morphogenesis. Philos Trans R Soc of Lond B Biol Sci 237:37-72 (1952).
82. Wolpert L. Positional information and the spatial pattern of cellular differentiation. J Theor Biol 25:1-47 (1969).
83. Wolpert L. Positional information revisited. Development Suppl 3-12 (1989).
84. Othmer HG, Maini PK, Murray JD (eds). Experimental and Theoretical Advances in Biological Pattern Formation. New York:Plenum Press, 1993.
85. Levin M. A Julia set model of field-directed morphogenesis: developmental biology and artificial life. Comput Appl Biosci 10:85-103 (1994).
86. Meinhardt H. Models of Biological Pattern Formation. London:Academic Press, 1982.
87. Oster GF, Murray JD. Pattern formation models and developmemal constraints. J Exp Zool 251:186-202 (1989).
88. Murray JD, Myerscough MR. Pigmentation pattern formation in snakes. J Theor Biol 149:339-360 (1991).